Small molecule · developed by Insmed
Amikacin liposome inhalation suspension is an aminoglycoside antibacterial delivered as a liposomal dispersion by nebulization. It is studied in Mycobacterium avium complex lung disease and in patients with cystic fibrosis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 4, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04677569 | Phase 3 | Mycobacterium Infections, Nontuberculous | Completed | INSM |
| NCT02628600 | Phase 3 | NTM Lung Infection Due to MAC | Completed | INSM |
| NCT02344004 | Phase 3 | Mycobacterium Infections, Nontuberculous | Completed | INSM |
| NCT01316276 | Phase 3 | Cystic Fibrosis | Completed | INSM |
| NCT03038178 | Phase 2 | Mycobacterium Infections, Nontuberculous | Completed | INSM |
| NCT01315236 | Phase 2 | Mycobacterium Infections, Nontuberculous | Completed | INSM |
| NCT03905642 | Phase 2 | Cystic Fibrosis | Completed | INSM |
| NCT00777296 | Phase 1/2 | Cystic Fibrosis | Completed | INSM |
| NCT06238856 | Phase 1 | Cystic Fibrosis | Completed | INSM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cystic FibrosisMycobacteria, AtypicalMycobacterium Infections, NontuberculousNTM Lung Infection Due to MAC
Updated Oct 18, 2026. Something wrong or missing? Report it on the INSM page.
See INSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INSM catalysts and pipeline →